Authors
Latest:
Open Science and Digital Health: A Brighter Future for Parkinson’s DiseaseCollaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
Leverage AI to Lower Cost, Barriers to Cell TherapiesOff-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system's rejection and navigating the FDA's approval process are crucial challenges.
Latest:
Harnessing AI for Pharma SalesArtificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Latest:
How A Self-Service Data Platform for Life Sciences Analytics Can Fast-Track Drug ReadinessOwning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.
Latest:
A Crossroads for the Digital Therapeutics Industry. Now is the Time to ActRecent events can provide digital therapeutics companies with clear lessons for the future.
Latest:
Why Machine Learning's Potential in Pharma Relies on Its TransparencyDespite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.
Latest:
Overcoming AI Bias Within Life SciencesHow to cultivate trust & connections in life sciences in a time of AI bias.
Latest:
Harnessing the Power of Communities to Combat Healthcare InequitiesBiopharma has a responsibility to meet patients where they are.
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
The Leap Forward: Practical Gains for Pharma AI UseExploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Latest:
The Emergence of Commercial Health Insurances as an Access Route to the Chinese MarketCommercial Health Insurance may bring more opportunities for market access in China.
Latest:
AI’s Promise in Delivering on Patient-CentricityHow pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
Latest:
Startup Launch Guide: Avoiding 10 Common Pain PointsWith opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Latest:
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime ValuePresenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Latest:
Three Key Steps to Unlocking mRNA’s Potential Beyond COVID-19Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.
Latest:
Digital Medicine and Pharma: The Partnerships Bringing Together Molecule and SoftwarePharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.
Latest:
Transforming Healthcare Data to Precision MedicineA modern healthcare ecosystem involves various stakeholders and many forms of complex data. Collaborations and a range of advanced approaches are essential to providing more uniform and complete healthcare to patients.
Latest:
The future of life sciences and healthcare v2Genpact’s latest report, Life Sciences and Healthcare in the Age of Instinct, explores three major trends shaping the future of healthcare.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
The Quest to Fully Address Prescription Drug AffordabilityThe Medicare Part D cap won’t solve need for financial assistance.
Latest:
The Rapid Growth of Remote Patient Monitoring Solutions Can Accelerate Decentralized Clinical TrialsPharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.
Latest:
Biopharma Needs a Health System Strategy to Secure Optimal Market AccessIn today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.
Latest:
How Good is a Good Product Launch?A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.
Latest:
Using GenAI as a Co-Pilot for Regulatory IntelligenceGenAI is on the precipice of breaking new ground in regulatory intelligence; making strategists more efficient by alleviating challenges, streamlining regulatory research and submission processes.
